Acarix Secures Important U.S. Reimbursement for CADScor System
Acarix, a prominent player in cardiac diagnostics leveraging AI technology, has recently reached a significant milestone with the U.S. Centers for Medicare & Medicaid Services (CMS). The company announced that the CPT code 0716T for the CADScor System has been assigned to APC 5733, with the status indicator being labeled as "S" (separately payable) for the approaching year. This pivotal decision means that the CADScor System can now receive standalone fixed reimbursement in outpatient environments.
The Impact of Guaranteed Reimbursement
Aamir Mahmood, the President and CEO of Acarix, expressed the significance of this ruling, stating, "Locking in guaranteed reimbursement for the CADScor System is a huge win for Acarix and will allow for rapid growth throughout the U.S. in a multitude of healthcare settings." This assurance of reimbursement signifies a shift towards a model where the system can be utilized independently, fostering clarity as the demand and application of the CADScor System potentially expands across U.S. healthcare facilities.
The Role of CMS in Expanding CADScor Usage
The CMS ruling suggests that when the CADScor System is implemented in various outpatient scenarios, including emergency rooms and ambulatory surgery centers, it will qualify for payment. This newly assigned code enables healthcare providers to navigate the reimbursement process through standard billing practices seamlessly.
Dr. George Chrysant, Chief Medical Officer for INTEGRIS Health Heart Hospital, remarked on the promising implications of the CMS decision, emphasizing that it could lead to increased usage of the CADScor System in emergency and outpatient settings throughout the country. He expressed confidence in the product’s capabilities and looks forward to the ongoing support from CMS, particularly in reviewing the reimbursement rates once the system gains widespread application.
Effect on Private Payer Reimbursement Decisions
Furthermore, the CMS decision is expected to have an influence on private payers as they typically turn to CMS guidelines when determining reimbursement policies. Mahmood highlighted the positive ripple effect that this decision could create among private payers throughout the United States, paving the way for accelerated growth of the CADScor System in the market.
About the CADScor System
The Acarix CADScor System stands as a groundbreaking, non-invasive diagnostic tool that utilizes AI to assess Coronary Artery Disease (CAD) accurately in under ten minutes, boasting an impressive 97% accuracy rate. Approval by both CE and FDA marks it as a safety-compliant option, supported by an extensive portfolio of patents and the successful diagnostics of over 40,000 patients exhibiting symptoms of chest pain.
Contact Information
For further inquiries, you can reach out to Ashley Wilson at Acarix by calling +1405 413 5201. Acarix is dedicated to establishing itself as a leader in the field of cardiac diagnostics, innovating solutions that radically enhance patient care.
About Acarix
Acarix is a Swedish medical device organization devoted to producing rapid and efficient diagnostic solutions for coronary artery disease. The Acarix CADScor System is designed for patients with chest pain and suspected CAD, reducing the prevalence of invasive and costly procedures. With a focus on precision, the CADScor System guarantees at least 96% proficiency in identifying significant coronary artery issues right at the point of care. Acarix is listed on the Nasdaq First North Premier Growth Market under the ticker ACARIX, and it is also accessible on the OTCQB market as ACIXF. The company’s commitment to improving healthcare access continues to drive its innovations.
Frequently Asked Questions
What is the CADScor System?
The CADScor System is an AI-powered diagnostic tool designed to assess Coronary Artery Disease (CAD) non-invasively and with high accuracy, providing results within minutes.
How does the CMS decision affect Acarix?
This decision allows Acarix to offer the CADScor System under a standalone reimbursement model, which can lead to increased utilization and growth in healthcare settings.
What is the significance of the "S" code for healthcare providers?
The "S" code indicates that the service is separately payable, giving healthcare providers the means to submit reimbursement claims using standard billing processes.
Why is private payer reimbursement affected by CMS decisions?
Private payers often look to CMS for precedents and guidelines when establishing their own reimbursement policies, so CMS decisions can heavily influence their rules.
How has the CADScor System been received in the market?
The CADScor System has been positively received, with usage on over 40,000 patients, which affirms its effectiveness and reliability in diagnosing CAD.
